Home Newsfeeds Marinus Pharmaceuticals Q3 EPS $1.89 Up From $(0.53) YoY

Marinus Pharmaceuticals Q3 EPS $1.89 Up From $(0.53) YoY

Marinus Pharmaceuticals (NASDAQ:MRNS) reported quarterly earnings of $1.89 per share. This is a 456.6 percent increase over losses of $(0.53) per share from the same period last year.

byBenzinga Newsdesk

November 7, 2022

1 minute read

Marinus Pharmaceuticals (NASDAQ:MRNS) reported quarterly earnings of $1.89 per share. This is a 456.6 percent increase over losses of $(0.53) per share from the same period last year.

Elon Musk Says 1st Optimus Bot Set To Walk By November With In-House Actuators

By Anan Ashraf

July 20, 2:09 AM

Musk said that no supplier produces the actuators required for the bot, leaving Tesla to design its own actuators that integrate the motor or the power electronics, the controller, and the sensors.

TSLA

New Shockwave Coronary IVL Publications Confirm Safety And Efficacy Across Multiple Calcium Morphologies

By Happy Mohamed

October 19, 8:39 AM

Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that two new publications reported

SWAV

Personalis Reports Preliminary Q4 And FY23 Revenue And Cash Balance; Sees Q4 Revenue $19.7M Vs $19.62M Est.; Sees FY23 Revenue $73.5M Vs $73.41M Est.

By Benzinga Newsdesk

January 5, 10:08 AM

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2023.Preliminary Fourth Quarter

PSNL